Takeda Pharmaceutical
330 hedge funds and large institutions have $1.25B invested in Takeda Pharmaceutical in 2025 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 134 increasing their positions, 77 reducing their positions, and 41 closing their positions.
1,201% more call options, than puts
Call options by funds: $25.3M | Put options by funds: $1.95M
74% more repeat investments, than reductions
Existing positions increased: 134 | Existing positions reduced: 77
41% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 41
4% more funds holding
Funds holding: 316 → 330 (+14)
4% more capital invested
Capital invested by funds: $1.2B → $1.25B (+$44.2M)
0.23% more ownership
Funds ownership: 2.45% → 2.68% (+0.23%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$44.6M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$27.8M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$23.9M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$21.2M |
| 5 |
AA
ABC Arbitrage
Paris,
France
|
+$8.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$39.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$9.93M |
| 3 |
Millennium Management
New York
|
-$7.91M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$6.14M |
| 5 |
BlackRock
New York
|
-$3.61M |
TAK Hedge Fund Activity: Q3 2025 in Review
330 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2025, worth a combined $1.25B — up 3.7% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new TAK positions and 41 closed out — a net gain of 17 holders — while 134 added to existing stakes and 77 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $44.6M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $39.2M sold.
- 330 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2025, up from 316 in Q2 2025.
- Funds reported $1.25B of Takeda Pharmaceutical stock for Q3 2025, up 3.7% quarter-over-quarter.
- 58 funds opened new Takeda Pharmaceutical positions in Q3 2025 and 41 closed out, a net change of +17 holders.
- The largest Takeda Pharmaceutical buyer in Q3 2025 was Toronto Dominion Bank, an estimated $44.6M added.
- The largest Takeda Pharmaceutical seller in Q3 2025 was Adage Capital Partners, an estimated $39.2M sold.
Based on aggregated 13F filings for Q3 2025.